Press release

Andreas Niedermaier becomes new CEO – Dr. Georg Weichselbaumer appointed to the Management Board effective July 1, 2019

Trostberg, June 3, 2019 – The Supervisory Board of AlzChem Group AG has decided to appoint Mr. Andreas Niedermaier (CFO) as the new CEO with effect from July 1, 2019, in view of the resignation of the current CEO Mr. Ulli Seibel as of December 31, 2019. In this function, Mr. Niedermaier will also be responsible for Investor Relations and Communications. Dr. Georg Weichselbaumer was newly appointed to the Management Board effective July 1, 2019. Dr.

We are AlzChem!

The AlzChem image film presents the company as a group that focuses on know-how, research and technology – but that is also shaped by the people who work here. The four-minute video gives an insight into the heart of AlzChem, the production of calcium carbide in Hart, as well as an interesting overview of the company's other modern products. The main role, however, is played by the employees, whose commitment and community makes AlzChem an attractive employer who can look back on a long tradition and always has a vision for the future.

Synthetically produced creatine can alleviate creatine deficiency syndrome

At the first creatine deficiency syndrome (CCDS) symposium in Austin, Texas, which AlzChem sponsored, several patients reported positive treatment outcomes with creatine. Creatine is an endogenous substance produced in the liver and kidneys and is essential for energy supply to the brain, muscles and immune system. In people with creatine deficiency syndrome (Cerebral Creatine Deficiency Syndrome, CCDS), the body’s creatine metabolism does not function properly, to word it simply, so that the brain is not supplied with creatine. “This disorder is congenital and has various manifestations.

Ein Blick über die Schulter und in die Zukunft

Einen Tag lang durfte Niklas Kahler aus Kastl, den beiden AlzChem-Chemikern Dr. Frank Eißmann und Dr. Sebastian Fischer-Messik über die Schulter schauen. Der 17-jährige Schüler des König-Karlmann-Gymnasiums Altötting hatte sich bei AlzChem um einen Schnuppertag mit einem Akademiker beworben und erhielt nun am 16. Juli die Gelegenheit, gleich zwei erfahrene Profis in ihre Berufswelt zu begleiten.

AlzChem research uncovers new synthesis route for amidines

Trostberg. Amidines are organic chemical compounds with an NCN structure, meaning a typical nitrogen-carbon-nitrogen sequence. These types of chemicals are one of AlzChem’s core competencies. NCN structures are contained in many biologically active molecules, which is why a general new synthesis method is so important to the development and production of active ingredients in pharmaceuticals and crop protection. Amidines to this point have been difficult to synthesize, particularly without substituents on nitrogen.

Graduation for young professionals

AlzChem released 39 trainees into professional life – well equipped and with excellent grades.

At a traditional ceremony on April 12, 2018, the management of AlzChem and BASF discharged 39 trainees. Of the 14 women and 25 men who have now completed their training, 34 will be taken on by AlzChem or BASF and five will leave the chemical park, two of them for further training.

Construction on the new CreAMINO® production plant officially underway

A traditional groundbreaking ceremony on March 16 officially opened construction on AlzChem Group AG’s new production plant in Trostberg for the feed additive CreAMINO®1. Dr. Peter Ramsauer (MdB), Klaus Steiner (MdL), District Administrator of Traunstein Siegfried Walch and Trostberg Mayor Karl Schleid were among AlzChem’s welcomed guests.

Majority shareholders offering shares to institutional investors

Today, our majority shareholders LIVIA Corporate Development SE, HDI Vier CE GmbH and Edelweiß Holding GmbH notified us of their intention to place up to 18,000,000 shares, corresponding to approximately 17.7% of AlzChem Group AG 's share capital, with institutional investors via an accelerated bookbuilding. With this measure, our majority shareholders support the strategy of the Management Board of AlzChem Group AG which aims to increase the presence of the Company in the capital market, its free float and the liquidity of the shares.

About AlzChem Group AG